Biotechs' Rocky Road
Biotechs have taken a bit of a beating of late, with the Nasdaq Biotechnology Index off 18% from its high in February and flat for the year.
There doesn't seem to be any one thing to blame. Instead it's a combination of little things like worry over drug pricing and investors locking in gains after a long run.
Despite the tempered feelings about the sector, there's still growth to be had. Gilead Sciences should come close to generating its entire market cap in cash over the next seven years. But investors should be careful when looking at companies such as Orexigen and GW Pharma , which have shot up on limited news.
Watch the video below where senior biotech specialist Brian Orelli and health-care bureau chief Max Macaluso discuss the prospects for Gilead, Orexigen, GW Pharma, and the rest of the industry.
The high-tech industry just keeps on giving
If you thought the iPod, the iPhone, and the iPad were amazing, just wait until you see this. One hundred of Apple's top engineers are busy building one in a secret lab. And an ABI Research report predicts 485 million of them could be sold over the next decade. But you can invest in it right now... for just a fraction of the price of AAPL stock. Click here to get the full story in this eye-opening new report.
The article Biotechs' Rocky Road originally appeared on Fool.com.Brian Orelli has no position in any stocks mentioned. Max Macaluso, Ph.D. owns shares of Gilead Sciences. The Motley Fool recommends Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.